Zydus Lifesciences Ltd (ZYDUSLIFE)

Healthcare · Pharmaceuticals · NSE · Updated 1 September 2026
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
₹1,187 ↑ 21.02% (1Y)

🎯 Key Takeaways

  • Revenue grew 5.7% QoQ to ₹8,017 in Q1FY27.
Market Cap
₹1.18 L Cr
P/E Ratio
26.4
P/B Ratio
4.37
ROE
16.6%
ROCE
16.8%
Debt/Equity
0.43
Div Yield
0.08%
Promoter
75.0%

📊 Quarterly Results (₹ Cr)

MetricSep 2025Dec 2025Mar 2026Jun 2026
Revenue6,1236,8657,5878,017
Operating Profit1,7141,4572,0461,375
OPM %28.0%21.2%27.0%17.1%
Net Profit1,2339651,341952
EPS₹12.51₹10.36₹12.65₹9.35

🏦 Balance Sheet (₹ Cr)

ItemMar 2025Mar 2025Mar 2026Mar 2026
Equity Capital101101101101
Reserves21,72423,85325,20127,011
Borrowings1913,2139,63611,770
Total Liabilities31,44637,20246,89752,407
Fixed Assets6,1026,0427,09926,639
Investments2,5966,4085,8787,540
Total Assets31,44637,20246,89752,407

💰 Cash Flow Statement (₹ Cr)

ItemMar 2026
Operating+2,117
Investing-8,296
Financing+5,807
Net Cash Flow-373

👥 Shareholding Pattern

CategoryQ2FY26Q3FY26Q4FY26Q1FY27
Promoters75.0%75.0%75.0%75.0%
FII7.3%7.1%7.0%6.9%
DII10.9%11.1%11.2%11.3%
Public5.5%5.5%5.5%5.5%
# Shareholders3,96,1054,03,2664,18,3143,99,251

⚖️ Peer Comparison — Pharmaceuticals

Company MCap (₹ Cr) P/E ROCE ROE D/E
SUNPHARMA 4.61 L Cr 38.1 18.7% 14.6% 0.05
DIVISLAB 2.46 L Cr 84.1 23.0% 17.4% 0.00
TORNTPHARM 1.92 L Cr 80.3 15.1% 25.7% 1.76
ZYDUSLIFE 1.18 L Cr 26.4 16.8% 16.6% 0.43
CIPLA 1.15 L Cr 34.0 13.2% 9.8% 0.01
LAURUSLABS 1.05 L Cr 95.5 20.8% 20.6% 0.45
LUPIN 99,448 17.6 27.9% 24.7% 0.26
MANKIND 98,599 48.2 13.9% 12.7% 0.38
DRREDDY 98,308 30.4 10.1% 8.4% 0.17
AUROPHARMA 94,937 25.8 12.8% 9.8% 0.20

📋 Recent Filings

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ZYDUSLIFE — Free

Free account · 2 AI queries/day